The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Japan’s Takeda Pharmaceutical Co. is suspending clinical trials of its anti-cholesterol drug known as TAK-475 because of potential side effects concerning the liver. The news comes in the wake of Congressional hearings investigating the FDA’s role in monitoring and evaluating pharmaceutical products. One interesting twist thus far in the hearings is how the FDA is supposed to monitor foreign pharmaceutical companies. This poses a problem with the sharp rise in drug output coming from such countries as India and China.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest